Real-Life Outcomes of Maraviroc-Based Regimens in HIV-1-Infected Individuals

Purpose: The use of maraviroc in our unit was reviewed with regard to efficacy and safety and also reviewed with regard to how our experience reflects the data presented in clinical trials. Methods: We utilized the pharmacy dispensary system to identify any patient dispensed maraviroc and conducted...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International Association of Providers of AIDS Care 2013-02, Vol.12 (1), p.12-14
Main Authors: Babiker, Zahir Osman Eltahir, Douthwaite, Sam Thomas, Collier, Lucy Elizabeth, Pennell, Ashley, Uriel, Alison J., Wilkins, Edmund
Format: Article
Language:English
Subjects:
Adult
Antiretroviral drugs
CD4 Lymphocyte Count
Clinical trials
Cyclohexanes - therapeutic use
Drug Hypersensitivity
Drug Therapy, Combination
Exanthema - chemically induced
Female
HIV
HIV Fusion Inhibitors - therapeutic use
HIV Infections - drug therapy
HIV-1 - genetics
Human immunodeficiency virus
Humans
Male
Medical treatment
Middle Aged
Patients
Pharmacy
Retrospective Studies
RNA, Viral - blood
Triazoles - therapeutic use
Viral Load
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: The use of maraviroc in our unit was reviewed with regard to efficacy and safety and also reviewed with regard to how our experience reflects the data presented in clinical trials. Methods: We utilized the pharmacy dispensary system to identify any patient dispensed maraviroc and conducted a case note review. Results: We identified 27 patients who have been prescribed maraviroc as part of their antiretroviral treatment. In all, 81% were men and 81% were white British. There were 26 treatment-experienced patients and 1 treatment-naive patient. At the time of switching to maraviroc, 17 patients had detectable HIV viral loads and 10 had HIV RNA levels
ISSN:2325-9574
2325-9582
2325-9582
DOI:10.1177/1545109712462454